

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT				SERIAL NO.		10/650,608	
				FILING DATE		28 Aug 2003	
				APPLICANT		Jean-Paul Cassart et al	
				GROUP		1642	
				EXAMINER		Min-Tam Davis	
				ATTORNEY DOCKET NO.		BC45300-1US	
U.S. PATENT DOCUMENTS							
Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
FOREIGN PATENT DOCUMENTS							
		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)							
	1	Arteaga (2002) "Trastuzumab, an appropriate first-line single-agent therapy for HER2-overexpressing metastatic breast cancer," <i>Breast Cancer Res.</i> 5:96-100.					
	2	Mitchell (2002) "Cancer vaccines, a critical review--Part II," <i>Curr Opin Investig Drugs.</i> 3:150-8					
	3	Reiter (1998) "Prostate stem cell antigen: A cell surface marker overexpressed in prostate cancer," <i>PNAS</i> 95:1735-1740.					
	4	Ross (2002) "Prostate Stem Cell Antigen as Therapy Target: Tissue Expression and <i>in Vivo</i> Efficacy of an Immunoconjugate," <i>Cancer Research</i> 62:2546-2553					
	5	Garcia-Hernandez (2008) "Prostate Stem Cell Antigen Vaccination Induces a Long-term Protective Immune Response against Prostate Cancer in the Absence of Autoimmunity," <i>Cancer Research</i> 68:861-869.					
	6	GlaxoSmithKline Biologicals, No. 001, "Antigen Specific Cancer Immunotherapeutics: Educating the patient's immune defense to fight cancer" (2007).					
EXAMINER					DATE CONSIDERED		
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.							